

Amniotics presents active biodistribution of stem cells to the brain

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announces positive experimental results with CogniStem, including high level of biodistribution of the stem cells to the brain tissue. The results opens up for potential applications within Alzheimer's, ALS, and Parkinsons disease.

As previously announced, the presentation took place at a symposium on stem cells hosted by Cold Spring Harbor Laboratory (CSHL) on Long Island, New York, June 3, 2023.

The study was an experimental model of hearing loss and altered pain perception, induced by chemotherapy. In the study, intravenous and intraarterial administration of CogniStem, Amniotics' neuro specific stem cell product of neonatal origin, was detected at significant levels in the brain tissue and was coupled with a significant increase of hearing acuity and decrease of neuropathic pain.

- We are very excited about these biodistribution results, which show that our neuro specific mesenchymal stem cells find their way across the blood-brain barrier and into the brain. This is a real game-changer for Amniotics, as this positions us in the highly expanding field of neurodegenerative disease treatment. Mesenchymal stem cells are proposed for treatment of devastating brain illnesses, such as Parkinson's, ALS and Alzheimer, but a big hurdle has been to get the cells to the brain in high enough amounts, especially when using the convenient route of injection in the bloodstream, says Amniotics CEO Marcus Larsson.

The next step in the development of CogniStem is continued preclinical development and evaluation, in collaboration with leading researchers at Lund university.

About CogniStem™

CogniStem is a neuro specific stem cell product of neonatal origin, derived from full-term amniotic fluid. CogniStem is expected to be efficacious in various central nervous system (CNS) diseases through modulation of the immune response and by supporting the recovery process.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Attachments

[Amniotics presents active biodistribution of stem cells to the brain](#)